3.15

0.32% 0.010

After Hours: 3.15

Phathom Pharmaceuticals Inc (PHAT)

Overview News Price History Option Chain Financials Discussions Forecast

Phathom Pharmaceuticals Inc stock is traded at $3.15, with a volume of 2.88M. It is up +0.32% in the last 24 hours and down -35.45% over the past month. Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Previous Close:

$3.14

Open:

$3.3

24h Volume:

2.88M

Relative Volume:

1.87

Market Cap:

$180.12M

Revenue:

Net Income/Loss:

$-297.11M

P/E Ratio:

-0.6069

EPS:

-5.19

Net Cash Flow:

$-216.95M

1W Performance:

+22.09%

1M Performance:

-35.45%

6M Performance:

-66.91%

1Y Performance:

-66.93%

1-Day Range:

$2.82

$3.3941

1-Week Range:

$2.21

$3.78

52-Week Range:

$2.21

$19.71

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name

Phathom Pharmaceuticals Inc

Sector

Healthcare (1154)

Industry

Biotechnology (676)

Phone

(877) 742-8466

Address

100 CAMPUS DRIVE,, FLORHAM PARK, NJ

Employee

427

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PHAT's Discussions on Twitter

Compare PHAT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHAT Phathom Pharmaceuticals Inc	3.15	180.12M	0	-297.11M	-216.95M	-5.19
VRTX Vertex Pharmaceuticals Inc	439.37	128.45B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	575.63	65.17B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	560.90	40.09B	2.58B	1.06B	-1.28B	16.33
ALNY Alnylam Pharmaceuticals Inc	270.19	35.67B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	233.25	27.44B	3.81B	-644.79M	-669.77M	-6.24

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-14-25	Initiated	Cantor Fitzgerald	Overweight
May-03-24	Initiated	Stifel	Buy
Jan-05-24	Reiterated	Needham	Buy
Aug-09-23	Initiated	H.C. Wainwright	Buy
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral
Feb-17-21	Initiated	BMO Capital Markets	Outperform
Feb-02-21	Initiated	Guggenheim	Buy
Jun-26-20	Downgrade	Goldman	Neutral → Sell
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Goldman	Neutral
Nov-19-19	Initiated	Jefferies	Buy
Nov-19-19	Initiated	Needham	Buy

View All

Phathom Pharmaceuticals Inc Stock (PHAT) Latest News

May 12, 2025

Phathom pharmaceuticals outlines VOQUEZNA expansion targets and cost-saving measures for profitability by 2026 - MSN

May 12, 2025

May 10, 2025

After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT) - MSN

May 10, 2025

May 09, 2025

Phathom Pharmaceuticals surges 50% following large insider purchase - MSN

May 09, 2025

Phathom Pharmaceuticals (PHAT) Shares Surge After Board Member's Large Purchase - GuruFocus

May 09, 2025

May 08, 2025

Insider Buying: Asit Parikh Acquires Additional Shares of Phathom Pharmaceuticals Inc (PHAT) - GuruFocus

May 08, 2025

May 05, 2025

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com

May 05, 2025

May 04, 2025

Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss - MSN

May 04, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price Target - Yahoo Finance

May 04, 2025

May 03, 2025

Phathom Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations - Yahoo

May 03, 2025

May 02, 2025

H.C. Wainwright cuts Phathom Pharma stock target to $20, keeps Buy rating - Investing.com Canada

May 02, 2025

Phathom Pharmaceuticals (PHAT) Price Target Lowered by Goldman Sachs | PHAT Stock News - GuruFocus

May 02, 2025

Phathom Pharmaceuticals (PHAT) Target Price Lowered by Guggenheim | PHAT Stock News - GuruFocus

May 02, 2025

Phathom Pharmaceuticals (PHAT) Maintains Buy Rating as Price Tar - GuruFocus

May 02, 2025

Phathom Pharmaceuticals (PHAT) Maintains Buy Rating as Price Target Drops | PHAT Stock News - GuruFocus

May 02, 2025

Phathom Pharmaceuticals (PHAT) Price Target Reduced by Guggenhei - GuruFocus

May 02, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 02, 2025

Phathom Pharmaceuticals (PHAT) Price Target Reduced by Guggenheim | PHAT Stock News - GuruFocus

May 02, 2025

PHAT Faces Price Target Cut Amidst Restructuring Efforts | PHAT Stock News - GuruFocus

May 02, 2025